Compare Stocks

Date Range: 

 VericelEditas MedicineBavarian Nordic A/SRevolution MedicinesSorrento Therapeutics
SymbolNASDAQ:VCELNASDAQ:EDITOTCMKTS:BVNRYNASDAQ:RVMDNASDAQ:SRNE
Price Information
Current Price$50.01$32.80$15.08$31.65$6.98
52 Week RangeBuyHoldN/ABuyBuy
MarketRank™
Overall Score1.11.60.81.71.3
Analysis Score1.44.00.03.53.5
Community Score2.52.12.72.73.2
Dividend Score0.00.00.00.00.0
Ownership Score1.71.70.01.70.0
Earnings & Valuation Score0.00.01.30.60.0
Analyst Ratings
Consensus RecommendationBuyHoldN/ABuyBuy
Consensus Price Target$49.71$46.50N/A$48.00$28.75
% Upside from Price Target-0.59% downside41.77% upsideN/A51.66% upside311.89% upside
Trade Information
Market Cap$2.32 billion$2.22 billion$2.88 billion$2.32 billion$2.00 billion
Beta3.112.11.55N/A2.7
Average Volume849,4712,257,2991,409626,85714,040,619
Sales & Book Value
Annual Revenue$117.85 million$20.53 million$99.33 million$50.04 million$31.43 million
Price / Sales19.67108.3629.0246.4563.66
Cashflow$0.27 per shareN/AN/AN/AN/A
Price / Cash183.98N/AN/AN/AN/A
Book Value$2.49 per share$5.12 per share$2.88 per shareN/A$0.20 per share
Price / Book20.086.415.2334.90
Profitability
Net Income$-9,660,000.00$-133,750,000.00$-51,980,000.00$-47,660,000.00$-292,070,000.00
EPS$0.18($2.68)($0.53)N/A($2.12)
Trailing P/E RatioN/AN/A21.850.00N/A
Forward P/E Ratio131.61N/A68.52N/A2.21
P/E GrowthN/AN/AN/AN/AN/A
Net Margins0.12%-99.62%31.17%-191.17%-698.01%
Return on Equity (ROE)0.13%-26.74%13.61%-32.25%-314.06%
Return on Assets (ROA)0.10%-16.38%6.86%-20.55%-43.60%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.07%N/A1.03%
Current Ratio5.88%9.25%1.74%11.39%1.15%
Quick Ratio5.41%9.25%1.54%11.39%1.13%
Ownership Information
Institutional Ownership Percentage93.11%87.52%N/A85.81%27.43%
Insider Ownership Percentage4.30%0.94%N/AN/A3.40%
Miscellaneous
Employees273235690125502
Shares Outstanding46.36 million67.83 million191.21 million73.44 million286.65 million
Next Earnings Date8/4/2021 (Estimated)8/5/2021 (Estimated)5/13/2021 (Estimated)8/9/2021 (Estimated)N/A
OptionableOptionableOptionableNot OptionableNot OptionableOptionable
SourceHeadline
SRNE Stock – LG Energy Solution to invest $4.5 billion in U.S. battery productionSRNE Stock – LG Energy Solution to invest $4.5 billion in U.S. battery production
fintechzoom.com - May 11 at 6:08 PM
The Trend in Sorrento TherapeuticsInc. (NASDAQ:SRNE) Continues to Point DownwardsThe Trend in Sorrento TherapeuticsInc. (NASDAQ:SRNE) Continues to Point Downwards
stocksregister.com - May 11 at 1:08 PM
SRNE Stock – TikTok Eyes Group Chat FeatureSRNE Stock – TikTok Eyes Group Chat Feature
fintechzoom.com - May 11 at 8:07 AM
SRNE Stock – Gold slides 2% to near three-week trough as U.S. yields surgeSRNE Stock – Gold slides 2% to near three-week trough as U.S. yields surge
fintechzoom.com - May 11 at 3:07 AM
SRNE Stock – US STOCKS-Strong economic data lifts Dow, S&P 500 to record closesSRNE Stock – US STOCKS-Strong economic data lifts Dow, S&P 500 to record closes
fintechzoom.com - May 10 at 10:06 PM
SRNE Stock – Crypto Market Value Exceeds $2 Trillion for First TimeSRNE Stock – Crypto Market Value Exceeds $2 Trillion for First Time
fintechzoom.com - May 9 at 10:46 PM
SRNE Stock – Sorrento (SRNE) Stock Has Over 700% Upside Potential, Says AnalystSRNE Stock – Sorrento (SRNE) Stock Has Over 700% Upside Potential, Says Analyst
fintechzoom.com - May 7 at 6:20 PM
SRNE Stock – Here are the 13 most expensive stocks to bet againstSRNE Stock – Here are the 13 most expensive stocks to bet against
fintechzoom.com - May 6 at 10:18 PM
SRNE Stock – XpresSpa Shares Are Facing More ProblemsSRNE Stock – XpresSpa Shares Are Facing More Problems
fintechzoom.com - May 6 at 2:16 AM
Sorrento Therapeutics Inc. [SRNE] Is Currently -7.96 below its 200 Period Moving Avg: What Dose This Mean?Sorrento Therapeutics Inc. [SRNE] Is Currently -7.96 below its 200 Period Moving Avg: What Dose This Mean?
dbtnews.com - May 5 at 3:59 PM
SRNE Stock – Ross Stores, Keysight Technologies & moreSRNE Stock – Ross Stores, Keysight Technologies & more
fintechzoom.com - May 5 at 10:58 AM
Moving Average Crossover Alert: Sorrento Therapeutics (SRNE)Moving Average Crossover Alert: Sorrento Therapeutics (SRNE)
finance.yahoo.com - May 5 at 10:58 AM
SRNE Stock – Russia Now Requires All Smartphones and Devices in the Country to Have Russian Software PreinstalledSRNE Stock – Russia Now Requires All Smartphones and Devices in the Country to Have Russian Software Preinstalled
fintechzoom.com - May 4 at 5:34 PM
Before You Invest, Make Sure You Check This Sorrento TherapeuticsInc. (NASDAQ:SRNE) AnalysisBefore You Invest, Make Sure You Check This Sorrento TherapeuticsInc. (NASDAQ:SRNE) Analysis
stocksregister.com - May 4 at 12:33 PM
SRNE Stock – What’s Next For Sorrento After A 35% Move In Last 5 Trading Days?SRNE Stock – What’s Next For Sorrento After A 35% Move In Last 5 Trading Days?
fintechzoom.com - May 4 at 7:33 AM
An in-depth look at the Sorrento Therapeutics Inc. (SRNE) stockAn in-depth look at the Sorrento Therapeutics Inc. (SRNE) stock
marketingsentinel.com - May 3 at 4:31 PM
SRNE Stock – Wall Street closes lower, ending three-day rally ahead of U.S. presidential debateSRNE Stock – Wall Street closes lower, ending three-day rally ahead of U.S. presidential debate
fintechzoom.com - May 3 at 10:15 AM
Sorrento Therapeutics (NASDAQ:SRNE) versus Halozyme Therapeutics (NASDAQ:HALO) Head to Head ReviewSorrento Therapeutics (NASDAQ:SRNE) versus Halozyme Therapeutics (NASDAQ:HALO) Head to Head Review
americanbankingnews.com - May 2 at 2:12 PM
What lies ahead for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) In 2020What lies ahead for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) In 2020
stocksregister.com - April 30 at 1:46 PM
Sorrento: The Monoclonal Antibody Portfolio Charges AheadSorrento: The Monoclonal Antibody Portfolio Charges Ahead
finance.yahoo.com - April 30 at 8:46 AM
Boom Or Bust: Where Does Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Stock Go From Here?Boom Or Bust: Where Does Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Stock Go From Here?
marketingsentinel.com - April 29 at 7:42 AM
Sorrento Therapeutics (NASDAQ:SRNE) Trading Down 3.9%Sorrento Therapeutics (NASDAQ:SRNE) Trading Down 3.9%
americanbankingnews.com - April 28 at 1:00 PM
Why Sorrento Therapeutics Stock Is Trading Higher TodayWhy Sorrento Therapeutics' Stock Is Trading Higher Today
msn.com - April 27 at 6:27 PM
Sorrento To Start Testing STI-3031 In Patients With Advanced Urothelial CarcinomaSorrento To Start Testing STI-3031 In Patients With Advanced Urothelial Carcinoma
finance.yahoo.com - April 27 at 6:27 PM
Sorrento Receives FDA Clearance to Proceed With Phase 2 Study for Sti-3031, an Anti-Pd-L1 ...Sorrento Receives FDA Clearance to Proceed With Phase 2 Study for Sti-3031, an Anti-Pd-L1 ...
apnews.com - April 27 at 1:27 PM
Time to Join Sorrento Therapeutics on its Next Leg UpTime to Join Sorrento Therapeutics on its Next Leg Up
marketbeat.com - April 21 at 8:43 AM
 Brokerages Anticipate Sorrento Therapeutics Inc (NASDAQ:SRNE) Will Post Quarterly Sales of $809.71 Million Brokerages Anticipate Sorrento Therapeutics Inc (NASDAQ:SRNE) Will Post Quarterly Sales of $809.71 Million
marketbeat.com - April 20 at 11:18 AM
DateCompanyBrokerageAction
5/6/2021VericelHC WainwrightBoost Price Target
3/3/2021VericelSVB LeerinkBoost Price Target
2/22/2021VericelBTIG ResearchBoost Price Target
2/16/2021VericelTruistBoost Price Target
1/19/2021VericelLADENBURG THALM/SH SHBoost Price Target
1/11/2021VericelOppenheimerDowngrade
12/17/2020VericelStephensInitiated Coverage
8/5/2020VericelNeedham & Company LLCInitiated Coverage
5/10/2021Editas MedicineMorgan StanleyLower Price Target
5/10/2021Editas MedicineRoyal Bank of CanadaInitiated Coverage
4/22/2021Editas MedicineThe Goldman Sachs GroupInitiated Coverage
3/29/2021Editas MedicineCredit Suisse GroupInitiated Coverage
3/8/2021Editas MedicineBarclaysReiterated Rating
2/28/2021Editas MedicineJPMorgan Chase & Co.Reiterated Rating
2/10/2021Editas MedicineChardan CapitalBoost Price Target
1/13/2021Editas MedicineWells Fargo & CompanyBoost Price Target
1/7/2021Editas MedicineRaymond JamesDowngrade
11/2/2020Editas MedicineRobert W. BairdInitiated Coverage
3/9/2020Revolution MedicinesCowenInitiated Coverage
3/9/2020Revolution MedicinesGuggenheimInitiated Coverage
1/29/2021Sorrento TherapeuticsB. RileyInitiated Coverage
1/21/2021Sorrento TherapeuticsAlliance Global PartnersInitiated Coverage
5/26/2020Sorrento TherapeuticsDawson JamesInitiated Coverage
10/7/2019Sorrento TherapeuticsJMP SecuritiesInitiated Coverage
(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.